Rosenlund, Signe

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

Mosenzon, O., Blicher, T. M., Rosenlund, S., Eriksson, J. W., Heller, S., Hels, O. H., Pratley, R., Sathyapalan, T., Desouza, C., Abramof, R., et al. (2019) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 351

Improved time in range over 1 year is associated with reduced albuminuria in individuals with sensor-augmented insulin pump-treated type 1 diabetes

Ranjan, A. G., Rosenlund, S. V., Hansen, T. W., Rossing, P., Andersen, S., & Nørgaard, K. (2020) · Diabetes Care

Diabetes Management and ResearchChronic Kidney Disease and Diabetes

Cited by 72

Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: Asub‐analysis of a randomized, placebo‐controlled, double‐blind, crossover trial

von Scholten, B. J., Persson, F., Rosenlund, S., Eugen‐Olsen, J., Pielak, T., Faber, J., Hansen, T. W., & Rossing, P. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 60

Effect of 4 years subcutaneous insulin infusion treatment on albuminuria, kidney function and HbA1c compared with multiple daily injections: a longitudinal follow‐up study

Rosenlund, S., Hansen, T. W., Andersen, S., & Rossing, P. (2015) · Diabetic Medicine

Diabetes Management and ResearchChronic Kidney Disease and Diabetes

Cited by 31

Effect of sensor-augmented pump treatment versus multiple daily injections on albuminuria: A 1-year randomized study

Rosenlund, S., Hansen, T. W., Rossing, P., & Andersen, S. (2015) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Management and ResearchChronic Kidney Disease and Diabetes

Cited by 19